Roche Holding AG (RHHBY)
| Previous close | 41.55 |
| Open | 42.12 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 41.91 - 42.20 |
| 52-week range | 37.88 - 53.86 |
| Volume | |
| Avg. volume | 2,104,612 |
| Market cap | 289.887B |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | 18.98 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.24 (2.99%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | N/A |
- Business Wire
Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results
SOUTH SAN FRANCISCO, Calif., August 02, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq® (atezolizumab) met its co-primary endpoints. The study showed non-inferior levels of Tecentriq in the blood (pharmacokinetics), when injected subcutaneously, compared with intravenous (IV) infusion, in cancer immunotherapy-naïve patients with locally advanced or metastatic non-smal
- GlobeNewswire
Roche’s subcutaneous formulation of Tecentriq demonstrates positive Phase III results
IMscin001 study showed non-inferior levels of cancer immunotherapy Tecentriq in the blood, when injected subcutaneously, compared to intravenous infusion, in people with advanced non-small cell lung cancerAdministered under the skin, the subcutaneous formulation reduces time spent receiving treatment to just minutes, compared with up to an hour for IV infusionData will be submitted to health authorities globally, including the US Food and Drug Administration and European Medicines Agency Basel,
- Business Wire
Genentech to Present Scientific Progress Across Alzheimer’s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting
SOUTH SAN FRANCISCO, Calif., July 28, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that data from 41 abstracts across its portfolio of Alzheimer’s disease pharmaceuticals and diagnostics will be presented at the 2022 Alzheimer’s Association International Conference (AAIC), which will be held in San Diego from July 31 - Aug. 4, 2022. Among the data are new presentations on Genentech’s investigational subcutaneous anti-amyloid monoclonal antibody gante
